

REMARKS

The Examiner has required restriction of pending Claims 1-3, 6, 9, 10, 12-23 and 26-30, and listed the following group classifications:

Group	Claims	Description
I	1-3 & 6	delta tryptase polypeptides
II	9, 10 & 12-14	methods of identifying modulators of delta tryptase
III	15-20	diagnostic methods comprising assaying expression of delta tryptase
IV	21-23	methods of identifying inhibitors of mast cell-mediated inflammation comprising detecting activity of delta tryptase
V	26-30	treatment methods comprising administering a modulator of delta tryptase to a subject

Applicants hereby elect to prosecute the claims of Group I (Claims 1-3 and 6), *without traverse*. Also, Applicants hereby elect as single species for examination purposes: **SEQ ID NO:2** (delta 1 tryptase) as a delta tryptase polypeptide; and **rheumatoid arthritis** as an inflammatory disease. In addition, Applicants hereby cancel Claims 26-30, and introduce new Claim 34, in order to further the prosecution of the present application and Applicants' business interests, yet without acquiescing to the Examiner's arguments, while reserving the right to prosecute the original, similar, or broader claims in one or more future application(s). Support for new Claim 34, directed to the delta 1 tryptase of SEQ ID NO:2, can be found but is not limited to original Claim 3. Thus no new matter has been introduced and Claims 1-3, 6 and 34 read upon the elected group and species.

Applicants respectfully request consideration of the references listed on the Information Disclosure Statement dated December 5, 2005, before the mailing of a first substantive Office Action. However, should the Examiner believe that a telephone interview would aid in the

prosecution of this application, Applicants encourage the Examiner to call the undersigned collect.

Dated: January 22, 2008

By: 

Christine A. Lekutis
Registration No. 51,934

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415.904.6500